222 related articles for article (PubMed ID: 12369870)
1. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era?
Honkanen RE; Golden T
Curr Med Chem; 2002 Nov; 9(22):2055-75. PubMed ID: 12369870
[TBL] [Abstract][Full Text] [Related]
2. Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases.
Honkanen RE; Codispoti BA; Tse K; Boynton AL; Honkanan RE
Toxicon; 1994 Mar; 32(3):339-50. PubMed ID: 8016855
[TBL] [Abstract][Full Text] [Related]
3. A Quantitative Chemical Proteomic Strategy for Profiling Phosphoprotein Phosphatases from Yeast to Humans.
Lyons SP; Jenkins NP; Nasa I; Choy MS; Adamo ME; Page R; Peti W; Moorhead GB; Kettenbach AN
Mol Cell Proteomics; 2018 Dec; 17(12):2448-2461. PubMed ID: 30228194
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3.
Woetmann A; Nielsen M; Christensen ST; Brockdorff J; Kaltoft K; Engel AM; Skov S; Brender C; Geisler C; Svejgaard A; Rygaard J; Leick V; Odum N
Proc Natl Acad Sci U S A; 1999 Sep; 96(19):10620-5. PubMed ID: 10485875
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C).
Swingle MR; Honkanen RE
Assay Drug Dev Technol; 2014 Oct; 12(8):481-96. PubMed ID: 25383722
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse.
Swingle M; Ni L; Honkanen RE
Methods Mol Biol; 2007; 365():23-38. PubMed ID: 17200551
[TBL] [Abstract][Full Text] [Related]
7. Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor.
Dounay AB; Forsyth CJ
Curr Med Chem; 2002 Nov; 9(22):1939-80. PubMed ID: 12369865
[TBL] [Abstract][Full Text] [Related]
8. Role of phosphoprotein phosphatases in the corpus luteum: I identification and characterisation of serine/threonine phosphoprotein phosphatases in isolated rat luteal cells.
Ford SL; Abayasekara DR; Persaud SJ; Jones PM
J Endocrinol; 1996 Aug; 150(2):205-11. PubMed ID: 8869587
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning, expression, and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC).
Huang X; Honkanen RE
J Biol Chem; 1998 Jan; 273(3):1462-8. PubMed ID: 9430683
[TBL] [Abstract][Full Text] [Related]
10. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Serine/Threonine Protein Phosphatases: Biochemical and Structural Studies Provide Insight for Further Development.
Swingle MR; Honkanen RE
Curr Med Chem; 2019; 26(15):2634-2660. PubMed ID: 29737249
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of serine/threonine phosphoprotein phosphatases alter circadian properties in Gonyaulax polyedra.
Comolli J; Taylor W; Rehman J; Hastings JW
Plant Physiol; 1996 May; 111(1):285-91. PubMed ID: 8685268
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells.
Messner DJ; Romeo C; Boynton A; Rossie S
J Cell Biochem; 2006 Sep; 99(1):241-55. PubMed ID: 16598789
[TBL] [Abstract][Full Text] [Related]
15. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A.
Honkanen RE
FEBS Lett; 1993 Sep; 330(3):283-6. PubMed ID: 8397101
[TBL] [Abstract][Full Text] [Related]
16. Serine/threonine protein phosphatases in apoptosis.
Klumpp S; Krieglstein J
Curr Opin Pharmacol; 2002 Aug; 2(4):458-62. PubMed ID: 12127881
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of protein phosphatases 1 and 2A differentially prevent intrinsic and extrinsic apoptosis pathways.
Chatfield K; Eastman A
Biochem Biophys Res Commun; 2004 Oct; 323(4):1313-20. PubMed ID: 15451440
[TBL] [Abstract][Full Text] [Related]
19. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
20. Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer.
Zhang Q; Fan Z; Zhang L; You Q; Wang L
J Med Chem; 2021 Jul; 64(13):8916-8938. PubMed ID: 34156850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
